cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cassava Sciences Inc
43 own
23 watching
Current Price
$28.91
$-0.09
(-0.31%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
960.73M
52-Week High
52-Week High
42.20000
52-Week Low
52-Week Low
8.79000
Average Volume
Average Volume
0.84M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization960.73M
icon52-Week High42.20000
icon52-Week Low8.79000
iconAverage Volume0.84M
iconDividend Yield--
iconP/E Ratio--
What does the Cassava Sciences Inc do?
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. It is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.
Read More
How much money does Cassava Sciences Inc make?
News & Events about Cassava Sciences Inc.
Globe Newswire
1 year ago
CHART 1 Decline in Cognition Scores, FAS CHART 2 Decline in Cognition Scores, patients with mild Alzheimer's Figure 1 Historical declines on ADAS-Cog over 18 months in Alzheimer's disease (MMSE 20-30), placebo arms vs simufilam treatment. Simufilam Slowed Cognitive Decline by 38% Versus ...
Globe Newswire
1 year ago
Overactive mTOR Plays a Key Role in Aging and Alzheimers Disease.Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect.Research is Published in Frontiers in Aging, a Peer-reviewed Journal. AUSTIN, Texas, June 27, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a ...
Globe Newswire
1 year ago
Publication Reviews Certain Receptor-Protein Interactions. Provides Overview of Basic Science Supporting Simufilam. Published in Drug Development Research, a Peer-Reviewed Journal. AUSTIN, Texas, June 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology ...
Globe Newswire
1 year ago
Over 1,244 Alzheimers patients now enrolled in Phase 3 studies of simufilam.Completion of patient enrollment for Phase 3 program still expected Q4 2023.$187.5 Million Cash and Cash Equivalents at March 31, 2023. AUSTIN, Texas, May 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a...
Globe Newswire
1 year ago
AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced that Remi Barbier, President & Chief Executive Officer, has been invited to present at the 2023 H.C. Wainwright BioConnect ...
Frequently Asked Questions
Frequently Asked Questions
What is Cassava Sciences Inc share price today?
plus_minus_icon
Can Indians buy Cassava Sciences Inc shares?
plus_minus_icon
How can I buy Cassava Sciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Cassava Sciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cassava Sciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Cassava Sciences Inc?
plus_minus_icon
What is today’s market capitalisation of Cassava Sciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cassava Sciences Inc?
plus_minus_icon
What percentage is Cassava Sciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cassava Sciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$28.91
$-0.09
(-0.31%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
OLEMA PHARMACEUTICALS INC
OLEMA PHARMACEUTICALS INC
$12.08
$-0.35 (-2.82 %)
Annexon Inc
Annexon Inc
$7.48
$0.00 (0.00 %)
89bio Inc
89bio Inc
$8.13
$-0.22 (-2.63 %)
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
$8.58
$0.05 (0.59 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
OLEMA PHARMACEUTICALS INC
OLEMA PHARMACEUTICALS INC
$12.08
$-0.35 (-2.82 %)
Annexon Inc
Annexon Inc
$7.48
$0.00 (0.00 %)
89bio Inc
89bio Inc
$8.13
$-0.22 (-2.63 %)
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
$8.58
$0.05 (0.59 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00